I think LIB-3 is consequential to our amendment to clause 40. Again, this was made in consultation with both the generics and the innovative medicines in trying to come up with a compromise that is acceptable to the stakeholders. Again, we hope it's acceptable to the members of this committee so that we can pass the amendment.
On December 14th, 2016. See this statement in context.